About Imcyse
Imcyse is a company based in Liege (Belgium) founded in 2010. It operates as a HealthTech and Professional Services. Imcyse has raised $57.25 million across 4 funding rounds from investors including Pfizer, Belfius and KU Leuven. The company has 48 employees. Imcyse offers products and services including Imotope TM Platform, IMCY-0141, and IMCY-0098. Imcyse operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, C4 Therapeutics, UCB and Erasca, among others.
- Headquarter Liege, Belgium
- Employees 48
- SectorsHealthcare
- Phone•••• ••••
- Website imcyse.com
- Social LinkedIn
- Legal Name Imcyse
- Net Profit-$10.6 M (USD)0as on Dec 31, 2018
- Total Equity Funding$57.25M (USD)
in 4 rounds
- Latest Funding Round$25.83M (USD), Series B
Feb 2021
- InvestorsPfizer
& 8 more
- Employee Count48
Products & Services of Imcyse
Imcyse offers a comprehensive portfolio of products and services, including Imotope TM Platform, IMCY-0141, and IMCY-0098.
Synthetic peptides are developed for targeted immune therapy.
Therapy is developed for treating Multiple Sclerosis patients.
Treatment is designed for Type 1 Diabetes management.
Funding Insights of Imcyse
Imcyse has successfully raised a total of $57.25M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $25.83 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $57.25M
- Total Rounds 4
- Last Round Series B — $25.83M
- First Round $2.24M
(Jun 2019)
- Investors Count 9
All 4 funding rounds of Imcyse with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2021 | $25.83M | Series B | – | Pfizer | |
| Jun 2019 | $2.24M | Debt – Conventional | – | – | |
| Jun 2019 | $31.42M | Series B | – | Life Sciences Partners | |
| Jun 2019 | $5.16M | Grant | – | – | – |
9 investors in total: 9 institutional.
Investors in Imcyse
Imcyse has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Pfizer, Belfius and KU Leuven.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Épimède is engaged in investing in high-growth technological SMEs. | – | epimede.com | Liège, Belgium | |
Private equity investments in life sciences businesses are managed. | 1998 | lspvc.com | Amsterdam, Netherlands | |
Noshaq is recognized as a Liège-based investment fund providing financing solutions. | – | noshaq.be | Liege, Belgium | |
Buyouts are pursued by SRIW as a private equity firm. | – | sriw.be | Liege, Belgium | |
Private equity is directed toward private and public companies. | – | sfpi-fpim.be | Brussels, Belgium | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | pfizer.com | New York, United States | |
Higher education is delivered through diverse courses and degrees. | 1425 | kuleuven.be | Leuven, Belgium | |
Bioinformatics platform developed for genomic data management and visualization. | 2021 | biogenosis-bioinfo.com | Rouen, France | |
Banking and insurance services are offered to individuals and businesses. | 1996 | belfius.be | Brussels, Belgium |
Investor details for Imcyse
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Imcyse
6 people are tracked at Imcyse (6 in leadership); the tracked headcount is 48.
| Name | Role | Group |
|---|---|---|
Denis Bedoret | CEO | Leadership |
Stefan Yee | Director – Representing AS Partners - Biogenosis | Leadership |
Andrew Mackie | Chief Business Officer | Leadership |
Hugues Wallemacq | Ph.d., Dmv, Director – Representing Noshaq Partners - Noshaq | Leadership |
Vincent G. Brichard | Ph.d., Director – Representing LSP 6 Holding | Leadership |
Antoon van Oosterhout | VP R&d - CSO | Leadership |
Complete people profiles for Imcyse
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Imcyse
3 dated milestones of Imcyse across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Imcyse is founded.
- Funding First funding round of $2.2M.
- Funding Latest funding round, Series B, of $25.8M.
Competitors of Imcyse
Imcyse operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, C4 Therapeutics, UCB and Erasca, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| ucb.com | 1928 | Brussels, Belgium | – | 79 | Therapies for immunological and neurological disorders are developed. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| grifols.com | 1909 | Barcelona, Spain | – | 18,309 | Plasma-derived therapies are developed to treat multiple diseases. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. |
Detailed competitors of Imcyse
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Imcyse
Complete news archive for Imcyse
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Imcyse
10 companies that operate in the same segment as Imcyse (Diabetes), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of devices for continuous glucose monitoring and manual insulin delivery | 2008 | San Diego, California, United States | USD 100.73 M | USD 1.02 B | 2,650 | |
Wearable glucose monitoring patches are provided for real-time data tracking. | 1999 | San Diego, California, United States | USD 52.5 M | USD 4.66 B | 10,300 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Small molecule drugs for various therapeutic areas are developed. | 1995 | United States | USD 165 M | USD 49.8 M | 103 | |
Implantable continuous glucose monitoring systems are provided for diabetes management. | 1996 | Germantown, United States | USD 175.46 M | USD 22.47 M | 117 | |
Developer of a closed-loop automated insulin delivery system | 2014 | Milpitas, California, United States | USD 214.51 M | – | 133 | |
Provider of workforce healthcare solutions | 2015 | New York, New York, United States | USD 107.87 M | – | 166 | |
Diabetes care and reversal programs are provided to patients. | 2021 | Bengaluru, Karnataka, India | USD 26.7 M | USD 5.07 M | 677 | |
Provider of smart devices for diabetes management for patients and doctors | 2014 | San Francisco, California, United States | USD 245.2 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 194 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Imcyse
Imcyse was founded in 2010 and raised its 1st funding round 9 years after it was founded.
Imcyse is headquartered in Liege, Belgium. It is registered at Liege, Liege, Belgium.
Denis Bedoret is the current CEO of Imcyse.
Imcyse is a funded company, having raised a total of $57.25M across 4 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $2.24M, raised on Jun 2019.
Imcyse has 48 employees.
Imcyse is engaged in the development of a novel class of targeted immunotherapies for severe, chronic autoimmune diseases. The companys proprietary Imotope TM platform utilizes synthetic peptides to recalibrate the immune system, addressing conditions such as Type 1 Diabetes, Multiple Sclerosis, Rheumatoid Arthritis, Neuromyelitis Optica, and Celiac Disease. Operations are supported through in-house advancements and strategic partnerships within the biopharmaceutical sector. Collaboration with academic institutions, industry partners, and funding from regional and European entities are integral to its growth. The focus remains on transforming treatment approaches for autoimmunity and related immune system disorders.
Imcyse's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Imcyse offers Imotope TM Platform, IMCY-0141, and IMCY-0098.
Imcyse has 9 investors. Key investors include Pfizer, Belfius, KU Leuven, Life Sciences Partners, and Biogenosis.
Imcyse operates through Imcyse.